Abstract 502: CSL112, a Novel Formulation of Human ApoA-I, Enhances the Capacity of Serum to Efflux Cholesterol from Macrophages

The ability of HDL to remove cholesterol from macrophages in atherosclerotic plaque is thought to underlie its inverse correlation with cardiovascular risk. Indeed, cholesterol efflux from macrophages is a functional serum marker that has an even stronger inverse association with coronary heart disease than HDL cholesterol (Khera et al. 2011, NEJM 364;2;127). We recently described CSL112, a novel…